Logo Logo Logo Logo Logo
  • COMPANY
    • ABOUT US
    • Management team
    • Board of Directors
    • Scientific Advisory Board
    • Business Development
    • Main Investors
    • CONTACT US
  • SCIENCE
    • SNP-Technology
    • Intellectual Property
  • PIPELINE
    • Overview
    • OCS-01 Diabetic macular edema
    • OCS-01 Post Cataract Surgery Inflammation
    • OCS-02 Uveitis
    • OCS-02 Dry Eye
  • NEWS
    • Press releases
  • CAREERS
  • COMPANY

    • ABOUT US
    • Management team
    • Board of Directors
    • Scientific Advisory Board
    • Business Development
    • Main Investors
    • CONTACT US
  • SCIENCE

    • SNP-Technology
    • Intellectual Property
  • PIPELINE

    • Overview
    • OCS-01 Diabetic macular edema
    • OCS-01 Post Cataract Surgery Inflammation
    • OCS-02 Uveitis
    • OCS-02 Dry Eye
  • NEWS

    • Press releases
  • CAREERS

Press Release 2020

OCULIS ESTABLISHES PRESENCE IN U.S. AND APPOINTS SYLVIA CHEUNG AS CHIEF FINANCIAL OFFICER 

 

September 1, 2020

OCULIS TO PRESENT AT THE UPCOMING 2020 SUMMER PRIVATE COMPANY SHOWCASE

 

August 10, 2020

OCULIS TO PRESENT AT THE LIFESCI PARTNERS PRIVATE COMPANY VIRTUAL SUMMER SYMPOSIUM

 

July 30, 2020

OCULIS ANNOUNCES SUCCESSFUL END-OF-PHASE 2 MEETING WITH THE FDA FOR OCS-01 IN TWO OPHTHALMOLOGY INDICATIONS

 

July 27, 2020

Contact us

Oculis Switzerland
Corporate Headquarters
EPFL Innovation Park Building D
Route J-D. Colladon
1015 Lausanne
Switzerland

+41 21 711 3970

 

Oculis Iceland
Alfheimar 74
6th Floor
104 Reykjavik
Iceland

+354 546 4440

Copyright © 2020 Oculis SA.

    © Oculis – Private policy

    © L’autreagence 2019